ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,109.34
-0.41%
S&P 500
5,304.72
0.70%
Dow Jones
39,069.59
0.01%
US Dollar vs Yen
156.8005
-0.03%
Brent Oil
82.825
-0.02%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NYSE
  6. Organon and Co (OGN)

  7. Organon and Co (OGN) ニュース

OGN

Organon (OGN)

Organon and Co
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NYSE:OGN
日付受信時刻ニュースソース見出しコード企業名
2024/05/2502 : 59Business WireL’Agence européenne des médicaments (EMA) entérine les dépôts de Henlius et d’Organon pour le candidat biosimilaire HLX14 de Prolia ® et Xgeva ® (denosumab)NYSE:OGNOrganon and Co
2024/05/2502 : 59Business WireEuropäische Arzneimittel-Agentur (EMA) validiert Einreichungen von Henlius und Organon für den Prolia ® und Xgeva ® (Denosumab) Biosimilar-Kandidaten HLX14NYSE:OGNOrganon and Co
2024/05/2500 : 29Business Wire欧州医薬品庁（EMA）、ヘンリウスとオルガノンによるProlia ® およびXgeva ® （デノスマブ）バイオシミラー候補HLX14を認証NYSE:OGNOrganon and Co
2024/05/2419 : 00Business WireEuropean Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14NYSE:OGNOrganon and Co
2024/05/1805 : 15Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
2024/05/0809 : 20Business WireOrganon Announces Pricing of $1.0 Billion Senior Notes OfferingNYSE:OGNOrganon and Co
2024/05/0805 : 07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
2024/05/0805 : 07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
2024/05/0805 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
2024/05/0805 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
2024/05/0805 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
2024/05/0805 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
2024/05/0805 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
2024/05/0720 : 58Business WireOrganon Announces Proposed $1.0 Billion Senior Notes OfferingNYSE:OGNOrganon and Co
2024/05/0220 : 30Business WireOrganon Reports Results for the First Quarter Ended March 31, 2024NYSE:OGNOrganon and Co
2024/04/0921 : 13Business WireProlia ® とXgeva ® （デノスマブ）との第3相比較臨床試験でバイオシミラー候補HLX1​​4が主要評価項目を達成NYSE:OGNOrganon and Co
2024/04/0903 : 31Business WireKlinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre EndpunkteNYSE:OGNOrganon and Co
2024/04/0903 : 31Business WireL'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primairesNYSE:OGNOrganon and Co
2024/04/0819 : 15Business WireOrganon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024NYSE:OGNOrganon and Co
2024/04/0819 : 00Business WirePhase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary EndpointsNYSE:OGNOrganon and Co
2024/03/0823 : 01PR Newswire (Canada)À l'occasion de la Journée internationale des femmes, Organon Canada encourage les entreprises à Investir en elle et à lutter contre les inégalités entre les genres par la santé des femmesNYSE:OGNOrganon and Co
2024/03/0823 : 01PR Newswire (Canada)On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's healthNYSE:OGNOrganon and Co
2024/03/0206 : 24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
2024/03/0206 : 24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
2024/03/0206 : 22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
2024/03/0206 : 22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
2024/02/2622 : 10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NYSE:OGNOrganon and Co
2024/02/2401 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:OGNOrganon and Co
2024/02/2022 : 00Business WireOrganon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National FormularyNYSE:OGNOrganon and Co
2024/02/1521 : 48Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
 Showing the most relevant articles for your search:NYSE:OGN

最近閲覧した銘柄

EU
C10
AMUNDI ETF GOVT BOND EUR...
COIN
QRXUSD
QuiverX
BIT
F17008
Vontobel Financial Produ...
EU
D090T
D090T
BIT
F16130
Vontobel Financial Produ...
BIT
AIGA
ETFS Agriculture
LSE
KGNP
Msci Chi Cl Usd
NASDAQ
CPTI
NASDAQ
DHCAW
DHC Acquisition
BIT
F17447
Vontobel Financial Produ...
GATE
ZODIETH
Zodium
COIN
STLBTC
DBI
I1C1
Xtr MSCI Europe ESG UCIT...
ASX
BSLKOR
BIT
UB93DN
Unicredit Bank
NASDAQ
ABAT
American Battery Technol...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有